Cortical phosphorylated α-Synuclein levels correlate with brain wave spectra in Parkinson's disease

Movement Disorders

Volumn 31, Issue 7, 2016, Pages 1012-1019

  Caviness, John N ^a   Lue, Lih Fen ^b,c   Hentz, Joseph G ^a   Schmitz, Christopher T ^b,c   Adler, Charles H ^a   Shill, Holly A ^b,d   Sabbagh, Marwan N ^b,d   Beach, Thomas G ^b   Walker, Douglas G ^b,c  

^a MAYO CLINIC   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

biochemistry; dementia; electroencephalography EEG; Parkinson's disease; synaptic proteins; synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; SYNAPTOPHYSIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TAU PROTEIN;

AGED; ARTICLE; AUTOPSY; BRAIN TISSUE; CINGULATE GYRUS; COHORT ANALYSIS; DEFAULT MODE NETWORK; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; HUMAN TISSUE; MALE; PARKINSON DISEASE; POSTERIOR CINGULATE; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 84977586579     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26621     Document Type: Article

References (47)

1. Caviness JN, Lue L, Adler CH, Walker DG. Parkinson's disease dementia and potential therapeutic strategies. CNS Neurosci Ther 2011;17:32-44.
2. Goldman JG, Williams-Gray C, Barker RA, Duda JE, Galvin JE. The spectrum of cognitive impairment in Lewy body diseases. Mov Disord 2014;29:608-621.
3. Beach TG, Adler CH, Lue L, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009;117:613-634.
4. Dickson DW, Fujishiro H, Orr C, et al. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord 2009;15(Suppl 3):S1-S5.
5. Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord 2014;29:634-650.
6. Swirski M, Miners JS, de Silva R, et al. Evaluating the relationship between amyloid-beta and alpha-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease. Alzheimers Res Ther 2014;6:77.
7. Sabbagh MN, Adler CH, Lahti TJ, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 2009;23:295-297.
8. Caviness JN, Hentz JG, Belden CM, et al. Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson's disease. J Parkinsons Dis 2015;5:117-124.
9. Fonseca LC, Tedrus GM, Letro GH, Bossoni AS. Dementia, mild cognitive impairment and quantitative EEG in patients with Parkinson's disease. Clin EEG Neurosci 2009;40:168-172.
10. Serizawa K, Kamei S, Morita A, et al. Comparison of quantitative EEGs between Parkinson disease and age-adjusted normal controls. J Clin Neurophysiol 2008;25:361-366.
11. Bousleiman H, Zimmermann R, Ahmed S, et al. Power spectra for screening parkinsonian patients for mild cognitive impairment. Ann Clin Transl Neurol 2014;1:884-890.
12. Olde Dubbelink KT, Stoffers D, Deijen JB, et al. Resting-state functional connectivity as a marker of disease progression in Parkinson's disease: a longitudinal MEG study. Neuroimage Clin 2013;2:612-619.
13. Olde Dubbelink KT, Hillebrand A, Stoffers D, et al. Disrupted brain network topology in Parkinson's disease: a longitudinal magnetoencephalography study. Brain 2014;137:197-207.
14. Lue LF, Walker DG, Adler CH, et al. Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol 2012;22:745-756.
15. Walker DG, Lue LF, Adler CH, et al. Changes in properties of serine 129 phosphorylated alpha-synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol 2013;240:190-204.
16. Pfefferkorn CM, Jiang Z, Lee JC. Biophysics of α-synuclein membrane interactions. Biochim Biophys 2012;1818(2):162-71.
17. Fantini J, Yahi N. The driving force of alpha-synuclein insertion and amyloid channel formation in the plasma membrane of neural cells: key role of ganglioside-and cholesterol-binding domains. Adv Exp Med Biol 2013;991:15-26.
18. Stockl MT, Zijlstra N, Subramaniam V. α-Synuclein oligomers: an amyloid pore? Mol Neurobiol 2013;47:613-621.
19. Leech R, Sharp DJ. The role of the posterior cingulate cortex in cognition and disease. Brain 2014;137:12-32.
20. Melzer TR, Watts R, MacAskill MR, et al. Grey matter atrophy in cognitively impaired Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83:188-194.
21. Rektorova I. Resting-state networks in Alzheimer's disease and Parkinson's disease. Neurodegener Dis 2014;13:186-188.
22. Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 2014;83:406-412.
23. Beach TG, Adler CH, Sue LI, et al. Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology 2015;35:354-389.
24. Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007;22:1272-1277.
25. Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27:349-356.
26. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707.
27. Obi K, Akiyama H, Kondo H, et al. Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies. Exp Neurol 2008;210:409-420.
28. Klassen B, Hentz J, Shill H, et al. Quantitative electroencephalography as a predictor for Parkinson's disease dementia. Neurology 2011;77:118-124.
29. Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006;281:29739-29752.
30. Fujiwara H, Hasegawa M, Dohmae N, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4:160-164.
31. Okochi M, Walter J, Koyama A, et al. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem 2000;275:390-397.
32. Colla E, Coune P, Liu Y, et al. Endoplasmic reticulum stress is important for the manifestations of alpha-synucleinopathy in vivo. J Neurosci 2012;32:3306-3320.
33. Colla E, Jensen PH, Pletnikova O, Troncoso JC, Glabe C, Lee MK. Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo. J Neurosci 2012;32:3301-3305.
34. Zaltieri M, Longhena F, Pizzi M, Missale C, Spano P, Bellucci A. Mitochondrial dysfunction and alpha-synuclein synaptic pathology in Parkinson's disease: who's on first? Parkinsons Dis 2015;2015:108029.
35. Bentea E, Van der Perren A, Van Liefferinge J, et al. Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated alpha-synuclein. Front Behav Neurosci 2015;9:68.
36. Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 2005;8:657-663.
37. Chen L, Periquet M, Wang X, et al. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 2009;119:3257-3265.
38. Bellucci A, Navarria L, Zaltieri M, Missale C, Spano P. alpha-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. Brain Res 2012;1432:95-113.
39. Caviness JN, Lue LF, Beach TG, et al. Parkinson's disease, cortical dysfunction, and alpha-synuclein. Mov Disord 2011;26:1436-1442.
40. Burre J, Sharma M, Sudhof TC. alpha-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc Natl Acad Sci U S A 2014;111:E4274-E4283.
41. Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC. alpha-Synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010;329:1663-1667.
42. Garcia-Reitbock P, Anichtchik O, Bellucci A, et al. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 2010;133:2032-2044.
43. Anticevic A, Cole MW, Murray JD, Corlett PR, Wang XJ, Krystal JH. The role of default network deactivation in cognition and disease. Trends Cogn Sci 2012;22:1689-1707.
44. Disbrow EA, Carmichael O, He J, et al. Resting state functional connectivity is associated with cognitive dysfunction in non-demented people with Parkinson's disease. J Parkinsons Dis 2014;4:453-465.
45. Yao N, Chang RS, Cheung C, et al. The default mode network is disrupted in Parkinson's disease with visual hallucinations. Hum Brain Mapp 2014;35:5658-5666.
46. Franciotti R, Pizzi SD, Perfetti B, et al. Default mode network links to visual hallucinations: a comparison between Parkinson's disease and multiple system atrophy. Mov Disord 2015;30:1237-1247.
47. Caviness JN. Pathophysiology of Parkinson's disease behavior—a view from the network. Parkinsonism Relat Disord 2014;20(Suppl 1):S39-S43.